GLPwatch
Papers (12034)
Page 91 of 201, ranked by citation count.
- Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
- Targeted pH switched europium complexes monitoring receptor internalisation in living cells.
- A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance.
- Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway.
- Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
- Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
- Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway.
- Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
- Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
- Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.
- Pre-Clinical Evaluation of a Modified Cyclodextrin-Based Nanoparticle for Intestinal Delivery of Liraglutide.
- Weight Recidivism After Bariatric Surgery: A Narrative Review.
- Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.
- Delayed Hypersensitivity Reaction to Liraglutide: A Case Report.
- Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes.
- Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.).
- Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.
- Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity.
- Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes.
- Effects of incretin agonists on endothelial nitric oxide synthase expression and nitric oxide synthesis in human coronary artery endothelial cells exposed to TNFα and glycated albumin.
- Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.
- An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs.
- Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond.
- Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A<sub>1C</sub> and Weight in Patients with Type 2 Diabetes.
- Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.
- EXENATIDE TREATMENT REDUCES THYROID GLAND VOLUME, BUT HAS NO EFFECT ON THE SIZE OF THYROID NODULES.
- Bullous Pemphigoid Triggered by Liraglutide.
- Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis.
- Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
- Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome.
- Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
- PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
- Semaglutide-Associated Acute Interstitial Nephritis: A Case Report.
- Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.
- A Glucagon-like Peptide 1 Analog Protects Mitochondria and Attenuates Hypoxia-Reoxygenation Injury in Cultured Cardiomyocytes.
- Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease.
- Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
- Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
- Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.
- Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
- Age-related change of GLP-1R expression in rats can be detected by [<sup>18</sup>F]AlF-NOTA-MAL-Cys<sup>39</sup>-exendin-4.
- Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4.
- Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.
- Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice.
- Study protocol of the randomised placebo-controlled GLOBE trial: <i>GL</i>P-1 f<i>o</i>r <i>b</i>ridging of hyperglyca<i>e</i>mia during cardiac surgery.
- The first case of psoriatic skin lesions exacerbation after liraglutide.
- Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
- Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY<sub>3-36</sub>, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats.
- Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases.
- A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers.
- The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.
- Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting.
- Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery.
- Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.
- Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.
- Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes.
- Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study.
- Liraglutide promotes apoptosis of HepG2 cells by activating JNK signaling pathway.
- Liraglutide Ameliorates β-Amyloid Deposits and Secondary Damage in the Ipsilateral Thalamus and Sensory Deficits After Focal Cerebral Infarction in Rats.